<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715178</url>
  </required_header>
  <id_info>
    <org_study_id>LCI-BCC-BIO-001</org_study_id>
    <nct_id>NCT04715178</nct_id>
  </id_info>
  <brief_title>Beat Childhood Cancer Specimen Banking and Data Registry</brief_title>
  <official_title>Specimen Banking With Clinical and Genomic Data Registry With the Establishment of Tumor Models for Pediatric Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giselle SaulnierSholler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational data registry study of all pediatric cancer patients at Atrium&#xD;
      Health (AH) and participating Beat Childhood Cancer Consortium sites involving specimen&#xD;
      banking and data collection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This observational registry and banking study is being performed on a large cohort of&#xD;
      patients who have been identified to receive molecular testing to better understand the&#xD;
      relationship between genomic and molecular information and clinical outcomes, enabling timely&#xD;
      and informed treatment decisions by physicians for cancer patients. We hypothesize that large&#xD;
      gene panels, sequencing (DNA/RNA), and epigenetics of tumors can identify molecular&#xD;
      aberrations in tumors that can be leveraged to offer more effective treatment. Findings may&#xD;
      suggest additional research will be required to better understand the molecular underpinnings&#xD;
      of the relationship between molecular abnormalities and disease. Banked specimens and the&#xD;
      creation of tumor cell lines and xenograft models will enable this research to be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2021</start_date>
  <completion_date type="Anticipated">January 2032</completion_date>
  <primary_completion_date type="Anticipated">January 2031</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Create a data registry of clinical and molecular/genomic data</measure>
    <time_frame>10 years</time_frame>
    <description>Create a data registry of clinical and molecular/genomic data from cancer patients who have undergone biopsy or surgical resection for clinical care to better understand the relationship between genomic and molecular information and clinical outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine number and types of genomic alterations within tumor types/subtypes</measure>
    <time_frame>10 years</time_frame>
    <description>Define genomic landscape of pediatric cancers through the determination of the number and types of genomic alterations within tumor types/subtypes, across tumor types, and tumor evolution over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the rate of actionable genomic alternations</measure>
    <time_frame>10 years</time_frame>
    <description>Evaluate the rate of actionable genomic alternations resulting in associated targeted therapies relative to all actionable genomic alterations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the correlation of baseline genomic alterations with clinical outcome.</measure>
    <time_frame>10 years</time_frame>
    <description>Evaluate the correlation of baseline genomic alterations with clinical outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bank additional specimens available for future research projects</measure>
    <time_frame>10 years</time_frame>
    <description>Bank additional specimens available for future research projects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Create cell line and xenograft models of pediatric cancers for future research</measure>
    <time_frame>10 years</time_frame>
    <description>Create cell line and xenograft models of pediatric cancers for future research</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pediatric Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with suspected or confirmed pediatric solid tumors</arm_group_label>
    <description>Patients with suspected or confirmed pediatric solid tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention- registry only</intervention_name>
    <description>No intervention- registry only</description>
    <arm_group_label>Patients with suspected or confirmed pediatric solid tumors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric cancer patients at participating Beat Childhood Cancer Consortium sites&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No age restrictions&#xD;
&#xD;
          -  Patients with suspected or confirmed pediatric solid tumors&#xD;
&#xD;
          -  Subject or his/her legally authorized representative (where applicable) signs the&#xD;
             study consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient or his/her legally authorized representative (where applicable) did not&#xD;
             consent for specimen banking and data collection for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giselle Sholler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beat Childhood Cancer at Atrium Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genevieve Bergendahl, MSN</last_name>
    <phone>704-381-9900</phone>
    <email>genevieve.bergendahl@atriumhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon McKee</last_name>
    <phone>704-381-9900</phone>
    <email>sharon.mckee@atriumhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Maxwell, RN</last_name>
      <phone>314-268-4000</phone>
    </contact>
    <investigator>
      <last_name>William Ferguson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Moore</last_name>
      <phone>980-442-2356</phone>
      <email>Abigail.Moore@atriumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Smith</last_name>
      <email>Lauren.Smith7@atriumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Javier Oesterheld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sydney Bargeloh</last_name>
      <phone>843-792-2957</phone>
      <email>BROWNSY@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Jaqueline Kraveka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.beatcc.org</url>
    <description>Beat Childhood Cancer Consortium website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Giselle SaulnierSholler</investigator_full_name>
    <investigator_title>Beat Childhood Cancer Chair</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

